NCT03334513

Refractive Error and Biometry in Retinopathy of Prematurity

Refractive and Biometric Outcomes in Patients With Retinopathy of Prematurity Treated With Intravitreal Injection of Ranibizumab as Compared With Bevacizumab - a Clinical Study of Correction at Three Years of Age

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 35 (actual)
• Sponsor: San Ni Chen · Academic / Other
• Sex: All
• Age: 3 Years – 3 Years
• Healthy volunteers: Not accepted

Summary

The investigators compared long-term refractive and biometric outcomes in children with retinopathy of prematurity who received two different anti-vascular endothelial growth factor agents.

Detailed description

Purpose: To compare refractive and biometric outcomes in patients with type 1 retinopathy of prematurity (ROP) treated with intravitreal injection of Ranibizumab (IVR), versus bevacizumab (IVB), at a corrected age of 3 years. Methods: A retrospective case series compared cycloplegic refractive statuses and biometric statuses in patients who received either IVR or IVB for Type 1 ROP, from April 2011 to April 2014. Comparison of refractive errors and biometric findings between the two groups was performmed and multivariate analysis of possible factors contributive to visual acuity was also performmed

Conditions

• Retinopathy of Prematurity

Interventions

Type	Name	Description
DRUG	Bevacizumab	intravitreal injection of bevacizumab
DRUG	Ranibizumab	intravitreal injection of ranibizumab

Timeline

• Start date: 2011-04-01
• Primary completion: 2014-04-01
• Completion: 2014-04-01
• First posted: 2017-11-07
• Last updated: 2017-11-07

Regulatory

• FDA-regulated drug study